Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

Dr Ducreux on Findings From the TRANSMET Trial in Colorectal Liver Metastases

August 12th 2024

Michel Ducreux, MD, PhD, discusses findings from the TRANSMET trial of chemotherapy plus liver transplantation in unresectable colorectal liver metastases.

Trastuzumab Deruxtecan Demonstrates Activity in HER2-Expressing Biliary Tract Cancer

August 10th 2024

Trastuzumab deruxtecan elicited responses in patients with HER2-positive biliary tract cancer, according to data from a single-arm, phase 2 trial.

Communication Is Key for Prioritizing Patients and Personalizing PDAC Care

August 9th 2024

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss the implications of a study evaluating reasons for non-treatment among patients with PDAC.

Real-World Study Reveals Reasons for Pancreatic Cancer Non-Treatment

August 7th 2024

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss common reasons for nontreatment among patients with pancreatic cancer.

Serial Clinical Response Evaluation Aids in Residual Disease Detection in ESCC

August 7th 2024

Bite-on-bite biopsies and endoscopic ultrasonography with fine needle aspiration were accurate in detecting MRD after neoadjuvant chemoradiotherapy in ESCC.

Dr Kelly on the Treatment and Heterogeneity of GIST

August 7th 2024

Ciara Kelly, MBBCh, BAO, discusses how the heterogeneity of GIST affects treatment decisions and the importance of testing for genetic abnormalities.

Dr Bekaii-Saab on the Benefits of Multidisciplinary Conferences in GI Cancer Care

August 7th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

EO-3021 Generates Responses in Advanced Solid Tumors Likely to Express CLDN18.2

August 6th 2024

EO-3021 was safe and led to responses in advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.

FDA Accepts sNDA for Cabozantinib in Advanced Pancreatic and Extra-Pancreatic NETs

August 6th 2024

The FDA has accepted a supplemental new drug application for cabozantinib in advanced pancreatic and extra-pancreatic neuroendocrine tumors.

FDA Awards Orphan Drug Designation to Avutometinib Plus Defactinib in Pancreatic Cancer

August 2nd 2024

The FDA granted an orphan drug designation to the combination of avutometinib and defactinib for use as a potential therapeutic option in patients with pancreatic cancer.

Future Outlooks in the Treatment of Metastatic Colorectal Cancer

August 1st 2024

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

Additional Key Takeaways of ASCO 2024 Data in mCR

August 1st 2024

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Evorpacept Plus TRP Yields Durable Responses in HER2+ Gastric/GEJ Cancer

July 31st 2024

Evorpacept plus TRP generated clinically meaningful, robust, and durable responses in patients with previously treated HER2-positive gastric or GEJ cancer.

Dr Bekaii-Saab on the Future of Treatment For Patients With GI Cancer

July 31st 2024

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

July 26th 2024

The EMA's CHMP has recommended zolbetuximab plus chemotherapy in select locally advanced unresectable or metastatic HER2-negative gastric or GEJ cancer.